Abstract

Glioblastoma contains a rare population of self-renewing brain tumor stem cells (BTSCs) which are endowed with properties to proliferate, spur the growth of new tumors, and at the same time, evade ionizing radiation (IR) and chemotherapy. However, the drivers of BTSC resistance to therapy remain unknown. The cytokine receptor for oncostatin M (OSMR) regulates BTSC proliferation and glioblastoma tumorigenesis. Here, we report our discovery of a mitochondrial OSMR that confers resistance to IR via regulation of oxidative phosphorylation, independent of its role in cell proliferation. Mechanistically, OSMR is targeted to the mitochondrial matrix via the presequence translocase-associated motor complex components, mtHSP70 and TIM44. OSMR interacts with NADH ubiquinone oxidoreductase 1/2 (NDUFS1/2) of complex I and promotes mitochondrial respiration. Deletion of OSMR impairs spare respiratory capacity, increases reactive oxygen species, and sensitizes BTSCs to IR-induced cell death. Importantly, suppression of OSMR improves glioblastoma response to IR and prolongs lifespan.

The suppression of the receptor for oncostatin M (OSMR) can prevent glioblastoma cell growth. Here, the authors demonstrate a role for OSMR in modulating glioma stem cell respiration and its impact on resistance to ionizing radiation.

Details

Title
OSMR controls glioma stem cell respiration and confers resistance of glioblastoma to ionizing radiation
Author
Sharanek Ahmad 1 ; Burban Audrey 1 ; Laaper Matthew 2 ; Heckel, Emilie 3 ; Joyal Jean-Sebastien 4 ; Soleimani, Vahab D 5 ; Jahani-Asl Arezu 6   VIAFID ORCID Logo 

 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774) 
 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); Montreal Neurological Institute, Integrated program in Neuroscience, Montréal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639) 
 Pharmacology and Ophthalmology, Université de Montréal, CHU Sainte-Justine, Departments of Pediatrics, Montréal, Canada (GRID:grid.416102.0); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
 Pharmacology and Ophthalmology, Université de Montréal, CHU Sainte-Justine, Departments of Pediatrics, Montréal, Canada (GRID:grid.14709.3b); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); McGill University, 3640 Rue University, Department of Human Genetics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
 Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000 0000 9401 2774); Montreal Neurological Institute, Integrated program in Neuroscience, Montréal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639); McGill University, Gerald Bronfman Department of Oncology and Division of Experimental Medicine, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2434619650
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.